Factoid: AZN has (by far) the lowest P/E of any Big Pharma. The low P/E may be deserved, however: http://www.bloomberg.com/news/2012-01-20/astrazeneca-may-rethink-aversion-to-big-deals.html Many people think AZN grossly overpaid for MEDI a few years ago.